573 related articles for article (PubMed ID: 36073783)
21. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome.
Berginc G; Bracko M; Ravnik-Glavac M; Glavac D
Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325
[TBL] [Abstract][Full Text] [Related]
22. Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients.
Kato A; Sato N; Sugawara T; Takahashi K; Kito M; Makino K; Sato T; Shimizu D; Shirasawa H; Miura H; Sato W; Kumazawa Y; Sato A; Kumagai J; Terada Y
Am J Surg Pathol; 2016 Jun; 40(6):770-6. PubMed ID: 26848797
[TBL] [Abstract][Full Text] [Related]
23. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics.
Lagerstedt Robinson K; Liu T; Vandrovcova J; Halvarsson B; Clendenning M; Frebourg T; Papadopoulos N; Kinzler KW; Vogelstein B; Peltomäki P; Kolodner RD; Nilbert M; Lindblom A
J Natl Cancer Inst; 2007 Feb; 99(4):291-9. PubMed ID: 17312306
[TBL] [Abstract][Full Text] [Related]
24. Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6.
Morak M; Käsbauer S; Kerscher M; Laner A; Nissen AM; Benet-Pagès A; Schackert HK; Keller G; Massdorf T; Holinski-Feder E
Fam Cancer; 2017 Oct; 16(4):491-500. PubMed ID: 28528517
[TBL] [Abstract][Full Text] [Related]
25. Associations of Pathogenic Variants in MLH1, MSH2, and MSH6 With Risk of Colorectal Adenomas and Tumors and With Somatic Mutations in Patients With Lynch Syndrome.
Engel C; Ahadova A; Seppälä TT; Aretz S; Bigirwamungu-Bargeman M; Bläker H; Bucksch K; Büttner R; de Vos Tot Nederveen Cappel WT; Endris V; Holinski-Feder E; Holzapfel S; Hüneburg R; Jacobs MAJM; Koornstra JJ; Langers AM; Lepistö A; Morak M; Möslein G; Peltomäki P; Pylvänäinen K; Rahner N; Renkonen-Sinisalo L; Schulmann K; Steinke-Lange V; Stenzinger A; Strassburg CP; van de Meeberg PC; van Kouwen M; van Leerdam M; Vangala DB; Vecht J; Verhulst ML; von Knebel Doeberitz M; Weitz J; Zachariae S; Loeffler M; Mecklin JP; Kloor M; Vasen HF; ;
Gastroenterology; 2020 Apr; 158(5):1326-1333. PubMed ID: 31926173
[TBL] [Abstract][Full Text] [Related]
26. Lynch syndrome caused by a novel deletion of the promoter and exons 1-13 of MLH1 gene.
Huang J; Stinnett V; Jiang L; Chen S; Rodriguez F; Gocke CD; Zou YS
Cancer Genet; 2022 Apr; 262-263():91-94. PubMed ID: 35149321
[TBL] [Abstract][Full Text] [Related]
27. MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing.
Piñero TA; Soukarieh O; Rolain M; Alvarez K; López-Köstner F; Torrezan GT; Carraro DM; De Oliveira Nascimento IL; Bomfim TF; Machado-Lopes TMB; Freitas JC; Toralles MB; Sandes KA; Rossi BM; Junior SA; Meira J; Dominguez-Valentin M; Møller P; Vaccaro CA; Martins A; Pavicic WH
Fam Cancer; 2020 Oct; 19(4):323-336. PubMed ID: 32363481
[TBL] [Abstract][Full Text] [Related]
28. Prevalence of CNV-neutral structural genomic rearrangements in MLH1, MSH2, and PMS2 not detectable in routine NGS diagnostics.
Morak M; Steinke-Lange V; Massdorf T; Benet-Pages A; Locher M; Laner A; Kayser K; Aretz S; Holinski-Feder E
Fam Cancer; 2020 Apr; 19(2):161-167. PubMed ID: 32002723
[TBL] [Abstract][Full Text] [Related]
29. MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer.
Roberts ME; Jackson SA; Susswein LR; Zeinomar N; Ma X; Marshall ML; Stettner AR; Milewski B; Xu Z; Solomon BD; Terry MB; Hruska KS; Klein RT; Chung WK
Genet Med; 2018 Oct; 20(10):1167-1174. PubMed ID: 29345684
[TBL] [Abstract][Full Text] [Related]
30. Multigene Panel Testing Provides a New Perspective on Lynch Syndrome.
Espenschied CR; LaDuca H; Li S; McFarland R; Gau CL; Hampel H
J Clin Oncol; 2017 Aug; 35(22):2568-2575. PubMed ID: 28514183
[TBL] [Abstract][Full Text] [Related]
31. Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing.
Soares BL; Brant AC; Gomes R; Pastor T; Schneider NB; Ribeiro-Dos-Santos Â; de Assumpção PP; Achatz MIW; Ashton-Prolla P; Moreira MAM
Fam Cancer; 2018 Jul; 17(3):387-394. PubMed ID: 28932927
[TBL] [Abstract][Full Text] [Related]
32. Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome.
Kastrinos F; Ingram MA; Silver ER; Oh A; Laszkowska M; Rustgi AK; Hur C
Gastroenterology; 2021 Aug; 161(2):453-462.e15. PubMed ID: 33839100
[TBL] [Abstract][Full Text] [Related]
33. Implication of DNA repair genes in Lynch-like syndrome.
Xicola RM; Clark JR; Carroll T; Alvikas J; Marwaha P; Regan MR; Lopez-Giraldez F; Choi J; Emmadi R; Alagiozian-Angelova V; Kupfer SS; Ellis NA; Llor X
Fam Cancer; 2019 Jul; 18(3):331-342. PubMed ID: 30989425
[TBL] [Abstract][Full Text] [Related]
34. Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.
Alqahtani M; Edwards C; Buzzacott N; Carpenter K; Alsaleh K; Alsheikh A; Abozeed W; Mashhour M; Almousa A; Housawi Y; Al Hawwaj S; Iacopetta B
Fam Cancer; 2018 Apr; 17(2):197-203. PubMed ID: 28643016
[TBL] [Abstract][Full Text] [Related]
35. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas.
Ju JY; Mills AM; Mahadevan MS; Fan J; Culp SH; Thomas MH; Cathro HP
Am J Surg Pathol; 2018 Nov; 42(11):1549-1555. PubMed ID: 30148743
[TBL] [Abstract][Full Text] [Related]
36. Comparison of screening strategies for Lynch syndrome in patients with newly diagnosed endometrial cancer: a prospective cohort study in China.
Chao X; Li L; Wu M; Ma S; Tan X; Zhong S; Bi Y; Lang J
Cancer Commun (Lond); 2019 Jul; 39(1):42. PubMed ID: 31307542
[TBL] [Abstract][Full Text] [Related]
37. Cancer Risk C (CR-C), a functional genomics test is a sensitive and rapid test for germline mismatch repair deficiency.
Alim I; Loke J; Yam S; Templeton AS; Newcomb P; Lindor NM; Pai RK; Jenkins MA; Buchanan DD; Gallinger S; Klugman S; Ostrer H
Genet Med; 2022 Sep; 24(9):1821-1830. PubMed ID: 35616648
[TBL] [Abstract][Full Text] [Related]
38. [Expression and clinical significance of MMR protein and MLH1 promoter methylation testing in endometrial cancer].
Jin W; Wang LQ; Liu Y; Liu AJ
Zhonghua Fu Chan Ke Za Zhi; 2018 Dec; 53(12):823-830. PubMed ID: 30585020
[No Abstract] [Full Text] [Related]
39. Molecular and Clinicopathologic Characterization of Mismatch Repair-Deficient Endometrial Carcinoma Not Related to MLH1 Promoter Hypermethylation.
Kaya M; Post CCB; Tops CM; Nielsen M; Crosbie EJ; Leary A; Mileshkin LR; Han K; Bessette P; de Boer SM; Jürgenliemk-Schulz IM; Lutgens L; Jobsen JJ; Haverkort MAD; Nout RA; Kroep J; Creutzberg CL; Smit VTHBM; Horeweg N; van Wezel T; Bosse T
Mod Pathol; 2024 Mar; 37(3):100423. PubMed ID: 38191122
[TBL] [Abstract][Full Text] [Related]
40. Characterization of germline mutations of MLH1 and MSH2 in unrelated south American suspected Lynch syndrome individuals.
Valentin MD; da Silva FC; dos Santos EM; Lisboa BG; de Oliveira LP; Ferreira Fde O; Gomy I; Nakagawa WT; Aguiar Junior S; Redal M; Vaccaro C; Valle AD; Sarroca C; Carraro DM; Rossi BM
Fam Cancer; 2011 Dec; 10(4):641-7. PubMed ID: 21681552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
